Dysrhythmia (also termed cardiac arrhythmia) refers to abnormal electrical activity in the heart resulting in irregular, too fast, or too slow rhythms. It ranges from benign extra beats requiring no treatment to life-threatening ventricular fibrillation requiring immediate intervention. Atrial fibrillation (AF) is by far the most prevalent clinically significant dysrhythmia in adults and the condition most relevant to ongoing medical aid cost management. As a CDL condition, medical aids must fund core medications — but the highest costs in dysrhythmia arise from procedural interventions and device therapy, where specialist shortfalls create the most significant out-of-pocket exposure.
Dysrhythmia Subtypes: What You Have Matters
The CDL category covers a range of conditions under the ICD-10 range I47–I49:
- Atrial fibrillation (AF): Most common significant arrhythmia; irregular atrial electrical activity causing uncoordinated atrial contractions. Risk of cardioembolic stroke is the primary danger — requiring anticoagulation.
- Atrial flutter: More organised than AF; rapid, regular atrial rate (~300 bpm); often co-exists with AF.
- Supraventricular tachycardia (SVT): Rapid regular rhythm originating above the ventricles; often paroxysmal; treatable by catheter ablation in most cases.
- Ventricular tachycardia (VT): Fast rhythm originating in the ventricles; can be haemodynamically destabilising; requires urgent management.
- Heart block / bradyarrhythmias: Slow rhythms due to conduction system disease; may require permanent pacemaker implantation.
CDL Coverage
Dysrhythmia is a CDL condition. Rate-control and rhythm-control medications, anticoagulants, and antiarrhythmics must be funded from the CDL benefit once registered. This covers the ongoing pharmacological management component — the most predictable cost layer. However, procedural costs are where the significant financial exposure occurs for most patients.
Medical Management
Rate control (AF): Beta-blockers (bisoprolol, metoprolol) or calcium channel blockers (diltiazem, verapamil) to control ventricular response rate. Inexpensive; well-established CDL formulary drugs.
Rhythm control (AF): Flecainide, propafenone (Class IC), amiodarone, sotalol (Class III). Amiodarone remains widely used in SA. Monthly cost: R300–R800 depending on agent and dose.
Anticoagulation (AF stroke prevention): Warfarin (historical standard, still used; requires INR monitoring) or NOACs (novel oral anticoagulants: apixaban/Eliquis, rivaroxaban/Xarelto, dabigatran/Pradaxa). NOACs are strongly preferred in current guidelines (no INR monitoring, fewer drug interactions, lower intracranial bleed risk). Monthly cost: R700–R850 for NOACs. Important: CDL formulary across schemes is not uniform — some schemes prefer warfarin under CDL minimum; NOAC coverage varies and exceptional-needs authorisation may be required for NOACs on some plans.
Procedural Interventions: Where Costs Escalate
Electrical cardioversion: External DC shock to restore normal sinus rhythm in AF or flutter. Relatively inexpensive as a procedure but requires hospitalisation.
Catheter ablation (electrophysiology study and ablation — EPS/RFA): Catheter introduced via femoral vein to locate and ablate (burn) the arrhythmia focus. The primary curative treatment for SVT (>90% success), AF (variable; 60–80% in appropriate patients), and some VTs. Cost: R60,000–R150,000 for the procedure before specialist shortfall. Electrophysiologist shortfall: R40,000–R120,000. Total out-of-pocket exposure: often R60,000–R150,000+. Gap cover is highly relevant for ablation procedures.
Permanent pacemaker implantation: For symptomatic bradycardia, heart block, or sick sinus syndrome. Device cost: R40,000–R80,000 (basic pacemaker) to R120,000+ (dual-chamber or rate-responsive device). Implant surgeon and cardiologist shortfalls add R30,000–R60,000. Gap cover recommended.
Implantable cardioverter-defibrillator (ICD): For patients with high risk of life-threatening ventricular arrhythmias (VT/VF). Device cost: R80,000–R150,000. Combined specialist shortfalls similar to pacemaker implantation. See Cardiomyopathy factsheet for additional ICD detail.
Annual Cost Estimates
| Scenario | Estimated Annual Cost |
|---|---|
| AF managed medically (rate control + warfarin) | R10,000 – R30,000 |
| AF managed medically (rate control + NOAC) | R20,000 – R45,000 |
| AF — single cardioversion + ongoing medication | R30,000 – R60,000 |
| SVT — catheter ablation (once-off, then cure) | R80,000 – R180,000 |
| AF — catheter ablation + ongoing medication | R100,000 – R200,000 |
| ICD/pacemaker implant year | R120,000 – R250,000 |
Gap Cover Relevance: High
The primary cost exposure in dysrhythmia is procedural — ablation, pacemaker, and ICD implantation. Specialist shortfalls for electrophysiology procedures are among the highest in cardiology. Gap cover with an OPL of approximately R220,000/year is strongly recommended for any patient with a known dysrhythmia where ablation or device therapy may be indicated.
Plan Selection: Key Questions
- Are NOACs (apixaban, rivaroxaban, dabigatran) funded under CDL, or is exceptional-needs authorisation required?
- What is the scheme's approved rate for electrophysiology procedures (EPS/ablation)?
- Are cardiac devices (pacemaker, ICD) funded through a dedicated device benefit, and if so, what is the rand value?
- Does the plan provide gap cover as an add-on, or does the co-payment structure require separate gap insurance?
Talk to Eldon
See which plans pay for dysrhythmia →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).
Understanding Your Monitoring Tests
Dysrhythmia diagnosis and ongoing monitoring relies on a suite of investigations that may or may not be clearly covered on your plan:
12-lead ECG: Basic; low cost; covered under most consultation benefits.
Holter monitoring (24–48 hour ambulatory ECG): Essential for documenting paroxysmal arrhythmias. Cost: R800–R1,800. Should be covered under diagnostic investigation benefit; confirm in advance.
Event monitor / loop recorder (long-term): Extended ambulatory monitoring for infrequent events. Implantable loop recorders (ILRs) for very infrequent syncope or suspected arrhythmia can cost R15,000–R25,000 for the device plus implantation. Pre-authorise explicitly.
Echocardiogram: Cardiac structural assessment — identifies underlying cardiomyopathy, valve disease, or structural heart disease contributing to arrhythmia. Cost: R2,000–R4,000. Covered under cardiology diagnostic benefit on most plans.
Electrophysiology study (EPS) without ablation: Diagnostic mapping study to characterise arrhythmia mechanism and location. May precede ablation. Cost: R30,000–R60,000. Pre-authorise.
Understanding which benefit covers each test — and whether benefit limits apply — prevents unpleasant surprises. A single comprehensive pre-ablation workup can involve multiple investigations across different benefit categories.